Medtech company Theraclion obtains €8.5 million in R&D funding from OSEO

23-Feb-2009 - France

Theraclion, developer for a treatment of hyperparathyroidism, announced that it has been granted €8.5 million in R&D funding by OSEO (the French state innovation agency) as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy. The ultrasound company SuperSonic Imagine will also participate in the Theraclion-driven project.

The €8.5 million in funding comes as a direct, €3.5 million grant and €5 million in reimbursable advances. In all, €6.9 million of the total amount will be attributed to Theraclion, with €1.6 million going to SuperSonic Imagine. After €500,000 in 2005 and €1.3 million in 2007, this is the third time that OSEO has provided Theraclion with financial support.

“We are particularly proud to see that OSEO has given our company a vote of confidence by awarding significant funding for the third time running. We shall pursue our clinical trials (the interim results of which are very convincing) and prepare the forthcoming commercialization of our products. We are the only company in the world to use ultrasound and our "UNIS" method in the treatment of hyperparathyroidism and our strategy is also to explore new clinical applications to broaden our field of opportunities,” says Ismaël Nujurally, CEO, Theraclion.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance